Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South America
Quantum BioPharma (NASDAQ: QNTM) has provided an update on Celly Nutrition Corp.'s signing of a Master Distribution Agreement with FUSION Distribution Group. This agreement covers Puerto Rico, The Caribbean, and parts of Central and South America. Celly Nutrition is launching unbuzzd™, an innovative beverage designed to support alcohol metabolism and promote alertness.
The partnership with FUSION, a leading brand incubator and distributor in the region, will introduce unbuzzd™ to new markets. The product is available on Amazon in Ready-to-Mix (RTM) powder sticks, with Ready-to-Drink (RTD) cans coming soon. FUSION's distribution network includes major retailers like Walmart, Walgreens, CVS, and Costco.
Celly Nutrition's CEO, John Duffy, formerly of Coca-Cola, and co-chair Gerry David, ex-CEO of Celsius Holdings, view this partnership as a significant opportunity for expansion in key vacation destinations where alcohol consumption is common.
Quantum BioPharma (NASDAQ: QNTM) ha fornito un aggiornamento sulla firma da parte di Celly Nutrition Corp. di un Master Distribution Agreement con il FUSION Distribution Group. Questo accordo copre Porto Rico, i Caraibi e alcune parti dell'America Centrale e Meridionale. Celly Nutrition sta lanciando un prodotto innovativo chiamato unbuzzd™, una bevanda progettata per supportare il metabolismo dell'alcol e promuovere l'attenzione.
La partnership con FUSION, un leader nell'incubazione di marchi e nella distribuzione nella regione, introdurrà unbuzzd™ in nuovi mercati. Il prodotto è disponibile su Amazon in stick di polvere pronti da mescolare (RTM), con lattine pronte da bere (RTD) in arrivo presto. La rete di distribuzione di FUSION include importanti rivenditori come Walmart, Walgreens, CVS e Costco.
Il CEO di Celly Nutrition, John Duffy, ex Coca-Cola, e il co-presidente Gerry David, ex CEO di Celsius Holdings, vedono questa partnership come un'opportunità significativa per l'espansione in destinazioni turistiche chiave dove il consumo di alcol è comune.
Quantum BioPharma (NASDAQ: QNTM) ha proporcionado una actualización sobre la firma de un Acuerdo Maestro de Distribución entre Celly Nutrition Corp. y FUSION Distribution Group. Este acuerdo abarca Puerto Rico, el Caribe y partes de América Central y del Sur. Celly Nutrition está lanzando un producto innovador llamado unbuzzd™, una bebida diseñada para apoyar el metabolismo del alcohol y promover la alerta.
La asociación con FUSION, un importante incubador de marcas y distribuidor en la región, introducirá unbuzzd™ en nuevos mercados. El producto está disponible en Amazon en sticks de polvo listos para mezclar (RTM), con latas listas para beber (RTD) que llegarán pronto. La red de distribución de FUSION incluye grandes minoristas como Walmart, Walgreens, CVS y Costco.
El CEO de Celly Nutrition, John Duffy, ex de Coca-Cola, y el copresidente Gerry David, ex CEO de Celsius Holdings, ven esta asociación como una oportunidad significativa para la expansión en destinos vacacionales clave donde el consumo de alcohol es común.
퀀텀 바이오파마(NASDAQ: QNTM)는 셀리 뉴트리션 코퍼레이션이 퓨전 유통 그룹과 체결한 마스터 유통 계약에 대한 업데이트를 제공했습니다. 이 계약은 푸에르토리코, 카리브해 및 중남미 일부 지역을 포함합니다. 셀리 뉴트리션은 알코올 대사를 지원하고 경각심을 촉진하기 위해 설계된 혁신적인 음료 unbuzzd™를 출시하고 있습니다.
이 파트너십은 지역의 주요 브랜드 인큐베이터이자 유통업체인 퓨전과 협력하여 unbuzzd™를 새로운 시장에 소개할 것입니다. 이 제품은 아마존에서 믹스 준비 완료(Ready-to-Mix, RTM) 파우더 스틱으로 구매할 수 있으며, 곧 음료수 준비 완료(Ready-to-Drink, RTD) 캔도 출시될 예정입니다. 퓨전의 유통 네트워크에는 월마트, 월그린스, CVS, 코스트코와 같은 주요 소매업체가 포함됩니다.
셀리 뉴트리션의 CEO인 존 다피(John Duffy, 이전 Coca-Cola 재직)와 공동 의장인 게리 데이비드(Gerry David, 이전 Celsius Holdings의 CEO)는 이 파트너십을 알코올 소비가 일반적인 주요 휴가지에서의 확장을 위한 중요한 기회로 보고 있습니다.
Quantum BioPharma (NASDAQ: QNTM) a fourni une mise à jour concernant la signature par Celly Nutrition Corp. d'un Accord de Distribution Principal avec le FUSION Distribution Group. Cet accord couvre Porto Rico, les Caraïbes et certaines parties de l'Amérique Centrale et du Sud. Celly Nutrition lance unbuzzd™, une boisson innovante conçue pour soutenir le métabolisme de l'alcool et promouvoir l'alerte.
Le partenariat avec FUSION, un incubateur de marques et distributeur réputé dans la région, introduira unbuzzd™ sur de nouveaux marchés. Le produit est disponible sur Amazon sous forme de sticks de poudre prêts à mélanger (RTM), avec des canettes prêtes à boire (RTD) à venir prochainement. Le réseau de distribution de FUSION comprend de grands détaillants tels que Walmart, Walgreens, CVS et Costco.
Le PDG de Celly Nutrition, John Duffy, ancien de Coca-Cola, et le co-président Gerry David, ancien PDG de Celsius Holdings, voient ce partenariat comme une opportunité significative d'expansion dans des destinations touristiques clés où la consommation d'alcool est courante.
Quantum BioPharma (NASDAQ: QNTM) hat ein Update zur Unterzeichnung eines Master-Vertriebsvertrages zwischen Celly Nutrition Corp. und der FUSION Distribution Group bereitgestellt. Dieser Vertrag umfasst Puerto Rico, die Karibik sowie Teile von Mittel- und Südamerika. Celly Nutrition bringt unbuzzd™ auf den Markt, ein innovatives Getränk, das den Alkoholstoffwechsel unterstützen und die Wachsamkeit fördern soll.
Die Partnerschaft mit FUSION, einem führenden Markeninkubator und Distributor in der Region, wird unbuzzd™ in neue Märkte einführen. Das Produkt ist auf Amazon als Fertigmischung (RTM) in Pulversticks erhältlich, während die Fertigtrinkdosen (RTD) bald folgen werden. FUSIONs Vertriebsnetz umfasst große Einzelhändler wie Walmart, Walgreens, CVS und Costco.
Der CEO von Celly Nutrition, John Duffy, ehemaliger Coca-Cola-Mitarbeiter, und Co-Vorsitzender Gerry David, ehemaliger CEO von Celsius Holdings, betrachten diese Partnerschaft als eine bedeutende Gelegenheit zur Expansion an wichtigen Urlaubszielen, wo Alkoholkonsum verbreitet ist.
- Signing of Master Distribution Agreement with FUSION Distribution Group for expanded market reach
- Launch of innovative product unbuzzd™ targeting alcohol metabolism and alertness
- Access to major retail customers including Walmart, Walgreens, CVS, and Costco
- Experienced leadership team with former executives from Coca-Cola and Celsius Holdings
- None.
Toronto, Ontario--(Newsfile Corp. - October 7, 2024) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma") provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu" or the "Company"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.
On October 7, 2024, Celly Nu announced signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and parts of Central and South America as follows:
Vancouver, BC - October 7, 2024 - Celly Nutrition Corp. ("Celly Nu" or the "Company"), led by CEO John Duffy, formerly Vice-President of National Sales of Coca-Cola, and co-chaired by Gerry David, former CEO of Celsius Holdings, has secured a master distribution agreement with FUSION Consulting Group ("Fusion"). Based in Puerto Rico, FUSION is a leading brand incubator and distributor of health-conscious food and beverages across Puerto Rico, the Caribbean, and parts of Central and South America. This partnership will bring unbuzzd™, Celly Nu's innovative alcohol metabolism supplement, to new markets through FUSION's robust distribution network.
unbuzzd's Ready-to-Mix (RTM) powder sticks are available now on Amazon in 3-packs and 18 packs, with Ready-to-Drink (RTD) 12oz cans coming soon. FUSION will handle distribution for both formats, alongside its impressive portfolio that includes CELSIUS, SHINE Water, Tona Cerveza, and Kin Whiskey.
John Duffy, CEO of Celly Nutrition Corp. stated, "Our partnership with FUSION marks a pivotal moment for unbuzzd. Their proven success in growing brands across the region will help us expand our footprint while delivering a functional, science-backed product. Eduardo Santacana and his team at FUSION are the perfect partners to help us introduce unbuzzd to consumers who seek a better way to enjoy alcohol responsibly."
Eduardo Santacana, CEO of FUSION Consulting Group, added: "It's an exciting opportunity to be part of unbuzzd's journey. This innovative product helps metabolize alcohol faster, promoting clarity and minimizing the aftereffects of drinking. We're eager to help bring unbuzzd's unique benefits to consumers across the Caribbean and beyond."
As unbuzzd™ enters key vacation destinations, where alcohol consumption is often part of the experience, the partnership with FUSION opens doors to major retail customers including Walmart, Walgreens, CVS, Costco, Sams, Farmacias Caridad, Pueblo Supermarkets, Supermax and many more.
About Celly Nutrition Corp.:
Celly Nutrition stands as a pioneering force in the wellness and recovery supplement landscape. With a commitment to innovation and quality, the company has secured an exclusive global licensing agreement with Quantum Biopharma Ltd., harnessing cutting-edge alcohol metabolizing technology for recreational uses. This strategic move positions Celly Nutrition as a leader in the development of science-driven solutions designed to enhance individual health and recovery processes, marking a new era in the support of responsible alcohol consumption.
About Fusion Distribution Group:
Fusion Consulting Group is a full-service, brand incubator distributor of Better For You! food & beverages in Puerto Rico & the Caribbean Basin. Fusion's differentiation is the passion & force by which launches & manages brands in its territory. Fusion's internal marketing department works closely with our partners to ensure a smooth and seamless integration to brand's identity, positioning and image.
About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, but not always, forward-looking information and statements can be identified by the use of words such as "plans", "expects", "intends", "estimates", "intends", "anticipates", or "believes" or the negative connotation thereof or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative connotation thereof. "Forward-looking information" includes, the Company's plans to launch its RTD (Ready to Drink) 12oz cans; and the benefits of the partnership with FUSION, including the bringing of unbuzzd™ to new markets through FUSION's distribution network, the expected expansion of Celly Nu's footprint, the bringing of unbuzzd's unique benefits to consumers across the Caribbean and beyond, and the partnership with FUSION opening the doors to major retail customers in key vacation destinations.
Such forward-looking information and statements are based on numerous assumptions, including the Company having the ability to launch its RTD (Ready to Drink) 12oz cans; and the Company having the ability to realize upon the stated benefits of the partnership with FUSION.
Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual events or results in future periods to differ materially from any projections of future events or results expressed or implied by such forward-looking information or statements, including, the Company's inability to launch its RTD (Ready to Drink) 12oz cans; and the Company's inability to realize upon the stated benefits of the partnership with FUSION.
Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.
There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.
The Company makes no medical, treatment or health benefit claims about unbuzzd™. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated any claims regarding unbuzzd™. The efficacy of such products have not been confirmed by approved research. Rigorous scientific research and clinical trials are needed. No clinical trials for the use of the Company's proposed products have been conducted. Any references to quality, consistency, efficacy and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884
Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/225788
FAQ
What is the new distribution agreement for Quantum BioPharma's (QNTM) Celly Nutrition?
What product is Celly Nutrition launching through this distribution agreement?
In what formats will unbuzzd™ be available through the FUSION distribution network?
Who are the key executives mentioned in relation to Celly Nutrition and Quantum BioPharma (QNTM)?
